Clinical Trials Logo

Clinical Trial Summary

Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk and dysregulation of immune response in front of infectious agents. The objective of this study is to evaluate the impact of undiagnosed and non-treated sleep disorders on innate immunity in a cohort of COVID-19 patients and the role of trained immunity induced by influenza vaccination in the innate immune response.


Clinical Trial Description

Sleep and immune system have reciprocal relationship. Sleep has a restorative role on immune system, influencing innate and adaptive immunity and sleep disorders can decrease immune response. Healthy innate immunity is crucial into regulation of the response against SARS-CoV-2. The hypothesis of the study is that the innate immunity response is blunted by sleep disorders and, this mitigated immune response, could influence on COVID-19 severity. Impaired immune response in patients with sleep disorders could be ameliorated inducing trained immunity by influenza vaccine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06341374
Study type Observational [Patient Registry]
Source Parc Taulí Hospital Universitari
Contact Andrea F Grau, Medicine
Phone +34608151458
Email andreagrau94@gmail.com
Status Recruiting
Phase
Start date November 6, 2023
Completion date September 30, 2024